Karyopharm Therapeutics (KPTI) was upgraded by Rodman & Renshaw to "strong-buy".
Karyopharm Therapeutics (KPTI) is now covered by Rodman & Renshaw. They set a "buy" rating on the stock.
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Karyopharm Therapeutics (NASDAQ:KPTI) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $15.00 price target on the stock.
Karyopharm Therapeutics Inc (KPTI) Q4 2025 Earnings Call Highlights: Revenue Growth Amidst ... [Yahoo! Finance]